• MustGrow Biologics published its MD&A for the three months ended March 31, 2026.
• NexusBioAg operations to close effective April 15, 2026; business re-sold third-party products; remaining inventory to be sold through existing channels.
• Continuing-operations revenue CAD 98,182; continuing-operations loss CAD 871,446; total loss CAD 1.32 million.
• Discontinued NexusBioAg sales CAD 1.67 million; loss CAD 451,299; assets held for sale CAD 2.09 million; related liabilities CAD 354,173.
• Working capital CAD 1.49 million at quarter-end, including cash CAD 419,577; operating cash outflow CAD 2.28 million; net proceeds CAD 1.78 million from 2026 Unit Offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MustGrow Biologics Corp. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.